Abducens nerve, 21, 22
Abscess, submucosal, 236
focal periodontal, 236
periapical, 242
Acanthosis nigricans, 150, 151
pigmentation in, 225
Acarbose, 89
contraindications, 89
Accessory nerve, 23, 24
Achlorhydria, 58
Acinic cell carcinoma, 274–275
Acquired immunodeficiency syndrome (AIDS), 128–130
Acromegaly, 103
Actinic cheilitis, 193, 194
Actinic keratoses, 244
Actinic lesions, 10
Acute myelogenous leukemia (AML), 70, 74
Addison disease, 93–95
pigmentation in, 225
Adenocarcinoma, 44, 240, 273
polymorphous low-grade, 231
Adenoid cystic carcinoma, 273, 275
Adenomas, 272–273
benign, 240
subtypes, 272
Adhesins, 111
Adhesion molecules, 191, 192
Adnexal skin tumors, 243
Adrenal cortex, 93–94
Adrenal cortex-pituitary axis, 94
Adrenal glands, 93–94
Adrenocortical insufficiency, 95
See also Addison disease
Albinism, 219
Albuminuria, 36, 38
Alcohol consumption, 3
cirrhosis, 56
Aldosterone
deficient, 94–95
elevated, 38
secretion, 94
Allergic drug reaction, 107t
Allergic fungal sinusitis, 178–179
Allergic reaction, 42–43, 43
Allergy patch testing, 24–25
Alopecia areata, 10
Alpha interferon, 269
Amphotericin B, 175–176
Amyloidosis, 237–238
Anaphylactic shock, 44, 52
Anemia, 67–70
See also individual names
Anesthesia
hypertension and, 40, 41
pulmonary disease and, 53
vasoconstrictors, 40–41
Anesthetic testing, 351
Angina pectoris, 32
Angina, during dental procedure, 33
Angioedema
clinical features, 250–251
corrrelates, 246–247
hereditary, 251
hypersensitivity in, 247
treatment, 251
Angiolympoid hyperplasia with eosinophilia, 250–251
Angiomas, 222–223
Angiotensin, 36
Angular cheilitis, 173
Anisocoria, 21–22
Anosmia, 20
Antibody-dependent cellular cytotoxicity, 114
Anticoagulant regimens, 34
analgesics and, 34
Antidiuretic hormone (ADH), 92–93
Antifungals, 174t
Antigens, 113
Antiretroviral medications, 132–133, 133t
Antral carcinoma, 50
Antral mucormycosis, 90
Aplastic anemia, 142, 143
Apical periodontitits, 69–70
Arteriolonephrosclerosis, 36
Ascites, management, 57
Aspirin
asthma and, 53
cogulation and, 62
with sulfonylureas, 92
toxicity, 65
Asthma, 42, 46
aspirin, 53
classification, 49t
corticosteroid use, 53
dental management, 52
drug allergy, 53
extrinsic, 49
intrinsic, 49
occupational, 49
risk, 4, 52
Atheromatous plaques/calcifications in diabetes, 87
on radiograph, 34
Atherosclerosis, 30–31
complications, 33–35
in diabetes, 87
hypertension and, 37
risk factors, 30
with thrombosis, 30, 33
Atherosclerotic thromboembolic vascular occlusive disease.
See atherosclerosis
Atrial fibrillation, 31
Atypical lymphoproliferative lesions, 241
Auditory nerve, 20
tests, 20
Aural diseases, 4
Azoospermia, 175–177
Azotemia, 36
Bacterial infections, 159–169
endocarditis, 160–163
late prosthetic joint infection, 163–166
in myelosuppressed patient, 75–76, 160
oral mucosal, 166–169
oral to secondary, 159
pathway, 159
Basal cell adenoma, 271–273
Basal cell carcinoma
clinical features, 243
corrrelates, 231
Rech's syndrome, 212
Biguanides, 89
Biliary atresia, 55
Bacterial infections, 159–169
endocarditis, 160–163
late prosthetic joint infection, 163–166
in myelosuppressed patient, 75–76, 160
oral mucosal, 166–169
oral to secondary, 159
pathway, 159
Basal cell adenoma, 271–273
Basal cell carcinoma
clinical features, 243
corrrelates, 231
Rech's syndrome, 212
Biguanides, 89
Biliary atresia, 55

Diabetes mellitus, 84
Diabetes insipidus, 92
Dexfenfluramine, 30
Cretinism, 96, 98
Craniopharyngioma, 44
Craniofacial growth, altered, 82
Dental instruments
Definitive diagnosis, 1
Cross-contamination, 185
Cushing disease, 95
Cushing syndrome, 38, 225
Cystic fibrosis, 45
Cytomegalovirus, 117, 124
Cytokines, 113
Cytomegalovirus, 117, 124
– 252
Cysts, 230
gingival, 236
benign lymphoepithelial, 237
Cytochrome P-450 enzyme system, 108
inhibitors of, 108, 109
Cytokines, 113
Cytomegalovirus, 117, 124
in HIV, 138–139
Definitive diagnosis, 1
Dental instruments
classification, 183
sterilization, 183–184
Denture papillomatosis, 149
Dermatitis herpetiformis, 59
Developmental mucosal conditions, 252–259
Dexfenfluramine, 30
Diabetes insipidus, 92–93
Diabetes mellitus, 84–92
adult onset, 84
angiopathies, 87
clinical features, 86–89
complications of, 4, 84, 86–87
correlates, 85–86
dental management, 91–92
dentist responsibility, 84
insulin-dependent, 84, 88
juvenile onset, 84
non-insulin-dependent, 84, 88
oral manifestations, 89–91
screening tests, 88
secondary, 84
symptoms, 87
– treatment, 88–89, 89
– type 1, 84–86, 87
– type 2, 84, 86, 87
Diabetic neuropathy, 87
Diagnostic blocks, 318
Diastole, 9–10, 27
Differential diagnosis, 1
Diphenhydramine, 52
Diplopia, 20
Double vision, 20
Drug-drug interaction, 107t, 108
Drugs, illicit, 3
headache, 337–338
Drug interactions, 107
Drug laboratory test interaction, 107t
Drug physiologic interaction, 107t, 107–108
Drugs reactions, adverse, 107–110
allergies, 109–110
at-risk patient, 107, 109
avoiding, 109–110
dental management, 109–110
dentist’s responsibility, 110
in HIV patients, 133
metabolism, 108
metabolized in liver, 156t
resources, 110
websites, 110t
– Dysgeusia, 20, 82
– Dyssomia, 20
– Dysplasia, 187–188, 195, 197
– Dyspnea, 49–50
– Ears, 11–12
– Ecchymoses, 61, 65
– skin, 80
– Ecchymosis, 221–222, 223
– Ectopic lymphoid tissue, 237, 238
– Edema, 4
– Eisenmenger complex, 29
– Electrocardiogram (EKG), 27–28
– abnormal, 31, 32
– analyzing, 28
– atrial repolarization wave, 28
– atrioventricular arrest, 31
– erratic, 31
– normal, 28
– P wave, 28, 31
– premature ventricular contractions, 31
– Q wave, 28
– QRS complex, 28, 31
– – R wave, 28
– – S wave, 28
– – sinus arrest, 31
– – S-T interval, 28
– – T wave, 28
– wandering pacemakers, 31
– Emphysema, 45, 46, 49
– Endocarditis, 29–30
– Endocarditis, bacterial, 160–163
– acute, 160
– cardiac conditions, 161t, 162
– causes, 160
– choosing antibiotics, 163
– clinical features, 161–162
– dental management, 162–163
– dental procedures
– not recommended, 162t
– recommended, 162t
– diagnosis, 162
– early symptoms, 162
– microbial organisms, 160t
– mouth rinses, 163
– pathogenesis, 161
– pathophysiology, 160–161
– presentation, 160
– prevention, 162
– prophylaxis, 163t
– responsibility of dentist, 162
– risk categories, 161t
– sites, 160
– sources, 163
– susceptibility, 162
– Endotoxin, 112
– Enterovirus enanthematous stomatitis, 125, 126
– Enteroviruses, 124–125
– correlates, 118
– crossover, 124
– diagnosis, 125, 126t
– subgroups, 119t
– treatment, 125
– Ephelides, 220
– Epidermolysis bullosa, 212–213
– Epinephrine, emergent, 52
– Epstein-Barr virus, 117, 118, 122
– in HIV, 138
– Erythema multiforme, 121, 122, 208, 213, 215
– clinical characteristics, 210
– immune complex vasculitis, 209
– immunofluorescent pattern, 207
– treatment, 213–217
– Erythrocytes, 67–68
– Erythropoietic polycythemia, 187, 193, 194
– Erythroplakia, 193
– Esophageal varices, 56
– Exophthalmos, 97
– Eye protection, 182
– Eyelid, 22–23
– ulcerated growths on, 244
– Eyes, external, 10
– cranial nerve testing, 21–23, 24
– papillary diameter, 21
– paresthesia, 50
– Facial nerve, 21, 23, 24
– Facial nerve palsy, 22
– Facial pain, atypical, 348–353
– anesthetic testing, 351
– assessment, 350
– brain activity studies, 349
– cause, 349, 353
– classification, 349
INDEX

clinical features, 349–350
consultation, 351
depression, 348–349
diagnosis, 350–351
differential diagnosis, 352t
etiology, 348–349
imaging, 350–351
peripheral trauma, 348
psychological/behavioral changes, 349
psychosocial problem, 349–350
role of dentist, 351–352
treatment, 351–353
Facial paresis, 22
Fanconi anemia, 68–69
Fen/fen, 30, 33
Fenfluramine, 30
Fibrin, 62
Fibrinogen, 61
Fibrous dysplasia, 103, 104
Fluorosis, 93
Focal epithelial hyperplasia, 150–151
Focal fibrous hyperplasia, 231
Focal infection theory, 159
Focal noncaseating granuloma, 247–248
Folic acid deficiency, 69
Fordyce granules, 256–257
Freckles, 220
Fungal infection, 136–137
Bipolaris, 179
in HIV, 136–137
invasive177–179
in myelosuppressed patient, 76–77
presentations, 136
in respiratory disease, 50
See also Candidiasis
Gag reflex, minimizing, 16
Gardner syndrome, 60
Gastric ulcers, 58
Gastrointestinal diseases, 57–60
Gastrointestinal system, 4
Genitourinary system, 5
Geographic tongue, 254–255
Giant cell arteritis, 336–337
Giant cell fibroma, 232
Gingiva, lymphoma in, 82
Gingival bleeding, 73, 77–78, 80
Gingival erosion, 93
Gingival fibromas, 231
Gingival hyperplasias, 234, 236
Gingival infiltrates, 77–78
Gingival inflammation, 90
Gingival leukemic infiltrate, 77
Gingival masses, 50
Gingival swellings, 230, 233
calcium channel blocker and, 237
Gingivitis, desquamative, 210
Gingivitis, hyperplastic, 230
Gingivostomatitis, 119
Glutazones, 89
Glomerulonephritis, 36, 39
Glossitis migrans, 254–255
Glossopharyngeal nerve, 21, 278, 279
Glossopharyngeal neuralgia, 342
Gloves, 182–183
latex allergy, 183
Glucose, blood levels, 88
Glucose-6-phosphate dehydrogenase deficiency, 68
Glutaraldehyde, 184
Glucose-6-phosphate dehydrogenase deficiency, 68
Glycemia, control of, 87
Glycosylated hemoglobin, 88
Goiter, 98
Gonorrhea, 167
Gorham disease, 150
Gorham-Stout disease, 150
Graft-versus-host disease, 82
Graft-versus-host disease, 82
Graft-versus-host disease, 82
granuloma, 76
Granulomatous inflammation, 236
specific, 245–246
stains for, 246
Graves disease, 96–98
Green teeth, 56
Hair, assessing, 10
Hairy tongue, 253–254
black/brown, 224, 225
Halitosis
causes, 282–284, 284t
clinical findings, 285
diagnosis, 287–288
patient examination, 284t
psychogenic, 284
salivary hypofunction, 282
treatment, 287–288
Hand, foot, and mouth disease, 125
Hand washing, 183
Hashimoto thyroiditis, 98
Hb A1c, 88
Head and neck
basic biopsy tray, 7
basic examination tray, 7
cancer, 369
categories, 6t
diseases, signs and symptoms, 4, 75
lesions, 6t
physical examination, 6t, 7t
primary elements of diagnosis, 7
vital signs, 7–10
Headache, 327–338
assessment, 328
carotid lesion, 336
cerebrospinal fluid pressure, 337
chronic paroxysmal hemicrania, 334–335
classification systems, 327–328, 328t
cluster, 333–334
cluster-trigeminal neuralgia, 334, 335t
dietary triggers, 338
facial pain, 328
giant cell arteritis, 336–337
head trauma, 335–336
hypertension, 328
infection, 337
medication contract, 333t
metabolic disorders, 338
migraine, 327, 328–331
abortive therapy, 331
with aura, 329
without aura, 329
diagnosis, 329
etiology, 328–329
facial, 329–330
management, 330–331, 331t
neurologic stimuli, 329
palliation, 331t
pathophysiology, 328–329
preventive protocols, 330
signs/symptoms, 329
variants, 330
nonvascular intracranial disorders, 337
prevalence, 327
rebound, 338
subarachnoid hemorrhage, 336
substance induced, 337–338
tension type, 331–333
trigeminal innervation, 328
tumors, 328, 337
vascular disorders, 336
vertigo, 335
withdrawal-induced, 337–338
Health care workers
exposure incidents, 183
protection of, 180–183
Hearing loss, 20
Heart, 8, 27–32
sounds, 28, 32
Heart failure, 29, 31
Heart murmur, 28, 30
functional, 33, 163
organic/functional, 33
Heart valves, 28–30
Heck disease, 150–151
Hemangioma, 258–259
intramuscular, 243
Liver disease

Hepatocellular carcinoma, 54
Herpes labialis, recurrent, 120
Herpangina, 125
Hereditary spherocytosis, 68
Herpes virus infection, 117
Hemolytic anemia, 68
Hemoglobin, 67
Hematocrit, 68
Hematemesis, 57
Hepatitis C virus
cirrhosis, 154
clinical features, 155–156
correlates, 154–155
dental management, 157–158
diagnosis, 155–156
leukocytosis, 155
neoplasia, 156
oral manifestations, 156
pathophysiology, 55–56
post-exposure protocol, 157–158
prevention, 157
replication, 153
serologic changes, 154
therapy, 156–157
vaccination, 157
Hepatitis C virus
cirrhosis, 154
clinical features, 155–156
correlates, 154–155
dental management, 157–158
diagnosis, 155–156
leukocytosis, 155
neoplasia, 156
oral manifestations, 156
portal hypertension, 154
post-exposure protocol, 157–158
replication, 153
serologic changes, 154
therapy, 156–157
Hepatitis B virus, 54
carrier state phases, 154
clinical features, 155–156
coagulopathy, 57
correlates, 152–154
dental management, 157–158
diagnosis, 155–156
neoplasia, 156
oral manifestations, 156
pathophysiology, 55–56
post-exposure protocol, 157–158
prevention, 157
replication, 153
serologic changes, 154
therapy, 156–157
vaccination, 157
Hepatitis C virus
cirrhosis, 154
clinical features, 155–156
correlates, 154–155
dental management, 157–158
diagnosis, 155–156
leukocytosis, 155
neoplasia, 156
oral manifestations, 156
porto-sinusoidal hypertension, 154
post-exposure protocol, 157–158
replication, 153
serologic changes, 154
therapy, 156–157
Hepatobiliary disease. See Liver disease
Hepatocellular carcinoma, 54–56
Hereditary spherocytosis, 68
Herpangina, 125
Herpes labialis, recurrent, 120–121, 122
Herpes simplex viruses, 117–122, 121
Herpes virus infection, 76, 77
mechanism, 112
Herpesviruses, 117–127
classes, 117
correlates, 117–118
description, 117, 118
diagnosis, 126
in HIV, 137
latency, 118
phases, 118
replication, 117–118
Herpetic whitlow, 119, 121
Histamine, 43
action of, 247
effect of, 44
Hepatitis C virus
Hepatitis virus infection, 117
Hepatitis virus infection, 117
Hepatitis B virus, 54
Heparin, 41, 66
Hemorrhagic pseudocysts, 105
Hemorrhagic pseudocysts, 105
Hemorrhage, oral, 80–81
Hemorrhagic diathesis, 61
Hemorrhagic diathesis, 61
Hemorrhagic pseudocysts, 105
Hypothyroidism, 4, 98
Hypertension, 27, 36–41
anesthesia and, 40, 41
classification, 39t
clinical features, 37–39
dental implications, 33
dental management, 40–41
emergent, 40
essential, 37–38
malignant, 38
medications for, 37–38
renal mechanisms in, 37
retraction cord and, 40
secondary, 38
Hyperthyroidism, 96–98
See also Graves disease
Hypersensitivity, 19, 21
Hypoadrenalocorticism, 4
Hypoglossal nerve, 23, 24
Hypoglycemia, 88
signs, 92
treatment, 88
unconsciousness, 92
Idiopathic intracranial hypertension, 337
Idiosyncratic drug reaction, 107t
IgE antibodies, 42, 43, 44
Illness, history of present, 2
Immune complexes
formation, 114
in heart disease, 29–30
in renal disease, 36
Immune response, 113–115
Immune system, review, 5
activity, 144, 145
in cancer 191
clinical features, 146–151
correlates, 144–146
histologic configuration, 146,
appearance, 146
in HIV, 139–140
lesions, 145t
neoplasia, 145, 151
precancerous, 150
treatment, 151
Hydroxychloroquine, 269
Hyperadrenalocorticism, 4
Hyperadrenalism, 95
Hyperaldosteronism, 38
Hypercalcemia, 101t
Hyperglycemia, 85–86
in diabetic neuropathy, 87
Hyperkeratosis, 187, 210
Hyperparathyroidism, 4, 101, 102
Hypertension, 27, 36–41
anesthesia and, 40, 41
classification, 39t
clinical features, 37–39
dental implications, 33
dental management, 40–41
emergent, 40
essential, 37–38
malignant, 38
medications for, 37–38
renal mechanisms in, 37
retraction cord and, 40
secondary, 38
Hyperthyroidism, 96–98
See also Graves disease
Hypersensitivity, 19, 21
Hypoadrenalocorticism, 4
Hypoglossal nerve, 23, 24
Hypoglycemia, 88
signs, 92
treatment, 88
unconsciousness, 92
Idiopathic intracranial hypertension, 337
Idiosyncratic drug reaction, 107t
IgE antibodies, 42, 43, 44
Illness, history of present, 2
Immune complexes
formation, 114
in heart disease, 29–30
in renal disease, 36
Immune response, 113–115
Immune system, review, 5
activity, 144, 145
in cancer 191
clinical features, 146–151
correlates, 144–146
histologic configuration, 146,
appearance, 146
in HIV, 139–140
lesions, 145t
neoplasia, 145, 151
precancerous, 150
treatment, 151
Hydroxychloroquine, 269
Hyperadrenalocorticism, 4
Hyperadrenalism, 95
Hyperaldosteronism, 38
Hypercalcemia, 101t
Hyperglycemia, 85–86
in diabetic neuropathy, 87
Hyperkeratosis, 187, 210
Hyperparathyroidism, 4, 101, 102
Hypertension, 27, 36–41
anesthesia and, 40, 41
classification, 39t
clinical features, 37–39
dental implications, 33
dental management, 40–41
emergent, 40
essential, 37–38
malignant, 38
medications for, 37–38
renal mechanisms in, 37
retraction cord and, 40
secondary, 38
Hyperthyroidism, 96–98
See also Graves disease
Hypersensitivity, 19, 21
Hypoadrenalocorticism, 4
Hypoglossal nerve, 23, 24
Hypoglycemia, 88
signs, 92
treatment, 88
unconsciousness, 92
Idiopathic intracranial hypertension, 337
Idiosyncratic drug reaction, 107t
IgE antibodies, 42, 43, 44
Illness, history of present, 2
Immune complexes
formation, 114
in heart disease, 29–30
in renal disease, 36
Immune response, 113–115
Immune system, review, 5
Immunocompromised patient precautions, 181
Immunoglobulins, 113, 114–115
Immunopathologic mucosal lesions, 206–217
correlates, 206–210
diagnosis, 206
differential diagnosis, 213, 216
treatment, 213–217
corticosteroids, 215–216
prednisone, 213–215
topical, 215–216
Immunosuppressed patient, 83
infection in, 76–77
Infection control, 180–185
aseptic technique, 185
barriers, 185
disinfection, 184–185
elements of, 181
equipment sterilization, 183–185
exposure incidents, 183
personal protection, 182–183
precautions, 180–181
work restrictions, 181t
Infection, in cancer patients, 368
Infection, mechanisms of, 111–116
barriers to, 112, 115
cellular cytotoxicity, 116
immunity, 114
latency, 111
microbial agents, 111–112
molecular mimicry, 111–112
odontogenic endodontic, 111
periodontal, 111
viral, 112
virulence, 111
virulence factors, 111t, 112, 112t
Inflammatory fibrous (denture)
hyperplasia, 232
Infraorbital paresthesia, 50
Innervation, 297–299
Insulin overdose, 88
Insulin preparations, 88t
Insulitis, 85
Interincisal maximal opening, 17, 19
International Normalized Ratio (INR), 34, 57, 64–65
normal, 65
Interstitial fibrosis, 46
Intraoral recurrent herpes, 121–122, 123
Intraoral sensory perception, 21
Intravascular hemostasis, 64
Iridal coloboma, 10
Iris, 10
Iron deficiency anemia, 68, 70
Irritable bowel symptoms, 58
Jaundice, 55, 56t
Jugular vein distention, 4
Kaposi sarcoma, 223
intraoral, 139, 140
treatment, 139
Keratinocytes, 188–191
Keratoacanthoma, 149
Keratoses, benign, 187–188
Ketosis, 86
Langerhans-cell histiocytosis, 93
Lanugo, 10
Laryngeal papillomatosis, 47
Laryngitis, 47
Laryngoscope, 17
Larynx
carcinoma, 44, 48
examining, 16–17
inflammation, 44
landmarks of, 18
leukoplakia, 44
Late prosthetic joint infection, 163–166
Advisory Statement, 165, 166
responsibility of dentist, 165
Leiomyoma, 239
Lesions
bulls eye, 213
cauliflower surface, 144
erthroplakic, 69
facial, 10
head, 6t
lichenoid, 24, 83, 208
oral, 57
papillary, 144–151
premalignant, 187, 192–194
skin, 59
upper airway, 4
verrucous, 144, 145t
Leukemia, 70–83
acute, 70, 71, 74
causes, 71
chronic, 70, 71, 74
clinical features, 73–74
correlates, 71–73
dental implications, 76
gingival infiltrates, 77–78
incidence, 70–71
mucositis, 79–80
oral hemorrhage, 80–81
oral infections in, 75–77
salivary gland dysfunction, 81
thrombocytopenia in, 62
treatment, 74
See also individual names
Leukocytes, maturation, 72
Leukoplakia, 187, 192
follow-up, 197
laser management, 199, 200
malignant transformation, 188t
as risk factor, 195
speckled, 193, 194
verrucous, 193, 194
Levothyroxine, 99
Lichen planus, 206–208
atrophic, 211
clinical characteristics, 210
erosive, 211, 216
follow-up, 217
histology, 206
immunofluorescent pattern, 207
immunoreactivity, 207, 208
reticular form, 210, 211
treatment, 213–217
Lichenoid changes, 83
Lichenoid lesions, 24, 83, 208
Linear gingival erythema, 141
Lingual compartment, 11–12
palpatation, 12
Lingual thyroid, 97
Lipid proteinosis, 39
Lipomas, 238, 239, 243
Lips, 13
dysesthesia, 40
examining, 11
palpatation, 12
paresthesia, 50
syphilis, 167
Liver cancer, 54
Liver disease, 4, 54–57
See also individual names
Liver failure, 57
Liver transplant patient, 57
Loose teeth, 93
Lungs
cancer, 46, 50
foreign body aspiration, 44
granulomatous infection, 44, 49
infection, 48–50
inflammatory disease, 44
interstitial fibrosis, 46
normal parenchyma, 44
tuberculosis, 44–45, 51
Lupus erythematosus, 210–213, 214
treatment, 213–217
Lymphadenopathy, 74–75
Lymphangiomata, 258–259
B Lymphocytes, 113–114
CD4 Lymphocytes, 113–115
Th pathways, 113–114
Lymphoma, 70,
clinical features, 241
correlates, 72–73
gingival infiltrates, 77–78
secondary, 73
types, 72, 73
Lymphonodular pharyngitis, 125
Lymphotropic viruses, 124
Malignant melanoma, 221
Breslow system, 220
Clark classification, 220, 222
Malleus, 11, 12
Osteoporosis, 103, 105
Osteoradionecrosis, 203
Otoscope, 11, 16

Pacemakers, 35
Pacemakers, wandering, 31
Paget’s disease, 103, 105

Pain, 289–310
analgesics, 56
assessing, 303–306
Axis I, 303, 304t, 305
Axis II, 303–306
in cancer patients, 367–370
chronic, 309
descriptors, 290t
diffuse, 299
disability questions, 304t
fast, 290
heterotopic, 299
illicit drugs and, 2
index of intensity, 304t
management, 34, 307–308
mechanisms, 289–301
mucositis, 79t, 79–80
musculoskeletal, 369
neurochemical factors, 293
neuroma, 343
neurochemical agents, 294t, 295
neural components, 289–291
neurotransmitters, 291
recognition, 289
through central nervous system, 299–300
transmission, 290–295

Pain and behavior
assessment, 303
Axis I, 303, 304t
Axis II, 303–307
chronic pain, 309
depression and vegetative symptom scales, 305t, 306t
depression, 303
factors, 303
functional evaluation, 303
issues, 302–306
management strategies, 307–308
modifiers, 303
patient interview, 306–307
positive findings, 306t
post traumatic stress disorder, 309
professional responsibility, 310
psychological consultation, 308–309
psychological disorders, 309–310
psychosocial contributors, 302
sleep recommendations, 308t
somatization, 303
somatization scale, 305t
suicidal, 310
Pain modulation, 34, 295–296, 296
behavioral factors, 296–297
descending inhibitory, 300
gate-control theory, 300
inhibitory control, 296, 300
peripheral control, 295
Pain-signal
detection, 289
gate-control theory, 300
neurochemical agents, 294t, 295
neuromodulation, 289–291
neurotransmitters, 291
recognition, 289
through central nervous system, 299–300
transmission, 290–295

Palate, 14
candidiasis, 175
eccymosis, 61
erythematous candidiasis, 135, 136
examining, 12
granuloma, 51
histoplasmosis, 177
jaundiced, 156
Kaposi sarcoma, 139
lymphoma, 51
perforated, 50
petechiae, 61
submucosal bleeding, 80
ulceration, 138
virus infection, 123, 126

Palpebral conjunctivae, 10
Papillary cystadenoma
lymphomatous, 272, 274
Papillomas, nasal, 43
Paralysis, 19
Paraneoplastic pemphigus, 209
Parathyromatosis, 100
Parathyroid disease, 100
Parathyroid hormone, 100
Paresthesia, 19, 21
infraorbital, 50
lower lip, 50
mental nerve, 51
Parotid gland tumors, 272, 273
Parotid tumor, 22
Pars flaccida, 11
Pars tensa, 11
Partial thromboplastin time (PTT), 64
Parulis, 236, 238
Patient ductus arteriosus, 29
Patient history, 1–5
category, 3t
for diabetes, 91
hepatitis, 157
HIV questionnaire, 134t
for infection, 181
medical, 2
parameters, 3t
system review, 3–5
Patient workup, 1–2
Pemphigus vulgaris, 209, 214, 216
clinical characteristics, 211
desmoglein, 209
immunofluorescent pattern, 207
treatment, 213–217
Periapical pathosis, 75
Periodontal abscess in diabetes, 90
Periostosis in diabetes, 92
Peripheral fibromas, 231
Peripheral neuropathy, 90–91
PERLA, 22
Petechiae, 61
Peutz-Jeghers syndrome, 58, 60
pigmentation in, 226
Phantom tooth pain, 344–346
Platelet aggregation, 61
Platelet adhesion, 61
Pioglitazone, 89
Pigmentation, 218
Pheochromocytoma, 38
Pigmentation, 218–227
albinism, 219
amalgam particles, 219, 220–221
blood pigments, 219
colors, 218
correlates, 219–226
diffuse, 224–226
focal, 220–224
macular, 218t
melanocytic lesions, 219
melanosomas, 219
multiple, 224–226
nodular, 218t
oral mucosa, 95
papillary, 218t
perioral macular, 60
physiologic, 224
tyrosinase, 219
Pigmentation, 218
Platelet adhesion, 61–62
Platelet aggregation, 61–62, 66
Platelet disorders, 62t
assessing, 64
clinical features, 64
Pleomorphic adenoma, 231, 273, 274
Pleuritis, 48
Plummer-Vinson syndrome, 69
Pneumoconiosis, 46, 50
Pneumonia, 44, 48–50
Polyomorphic low-grade adenocarcinoma, 275
Polyps, 57–58
adenomatous, 58, 60
hamartomatous, 58
intestinal, 58
Polyuria, 85, 92–93
Portal hypertension, 57 154
Postherpetic neuralgia, 342–343
Prednisone, 213–215
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sialolithiasis</td>
<td>270–271, 272</td>
</tr>
<tr>
<td>treatment</td>
<td>276</td>
</tr>
<tr>
<td>Sinoatrial node</td>
<td>27, 28, 31</td>
</tr>
<tr>
<td>Sinus arrhythmia</td>
<td>31</td>
</tr>
<tr>
<td>Sinus tachycardia</td>
<td>31</td>
</tr>
<tr>
<td>Sinuses</td>
<td>42</td>
</tr>
<tr>
<td>carcinoma in</td>
<td>44, 50</td>
</tr>
<tr>
<td>CT scan</td>
<td>48</td>
</tr>
<tr>
<td>symptoms</td>
<td>47</td>
</tr>
<tr>
<td>undifferentiated</td>
<td>44</td>
</tr>
<tr>
<td>neoplastic processes of</td>
<td>43–44</td>
</tr>
<tr>
<td>Sjögren syndrome</td>
<td>261–262, 264</td>
</tr>
<tr>
<td>diagnosis</td>
<td>266–267</td>
</tr>
<tr>
<td>histopathologic salivary glands</td>
<td>262</td>
</tr>
<tr>
<td>serologic markers</td>
<td>267</td>
</tr>
<tr>
<td>treatment</td>
<td>268–269</td>
</tr>
<tr>
<td>Sinus</td>
<td>42</td>
</tr>
<tr>
<td>Tachypnea</td>
<td>8</td>
</tr>
<tr>
<td>Tension type headache</td>
<td>312</td>
</tr>
<tr>
<td>referred</td>
<td>323</td>
</tr>
<tr>
<td>Symblepharon</td>
<td>10</td>
</tr>
<tr>
<td>Symptom</td>
<td>2</td>
</tr>
<tr>
<td>Syphilis</td>
<td>166</td>
</tr>
<tr>
<td>Systole, 8–9, 27</td>
<td>27</td>
</tr>
<tr>
<td>Tachypnea</td>
<td>8</td>
</tr>
<tr>
<td>Taste, 277–279–281</td>
<td>278</td>
</tr>
<tr>
<td>cranial nerves</td>
<td>278</td>
</tr>
<tr>
<td>terms, 278t</td>
<td>278</td>
</tr>
<tr>
<td>Taste disorders</td>
<td>277, 360</td>
</tr>
<tr>
<td>aging and, 279</td>
<td>282</td>
</tr>
<tr>
<td>clinical evaluation</td>
<td>286t</td>
</tr>
<tr>
<td>clinical findings</td>
<td>284–285</td>
</tr>
<tr>
<td>correlates</td>
<td>278–279</td>
</tr>
<tr>
<td>diagnosis</td>
<td>285–286</td>
</tr>
<tr>
<td>treatment</td>
<td>286</td>
</tr>
<tr>
<td>Taste receptors</td>
<td>278</td>
</tr>
<tr>
<td>Taste testing</td>
<td>20</td>
</tr>
<tr>
<td>Tattoos</td>
<td>221</td>
</tr>
<tr>
<td>Temperature, body</td>
<td>10</td>
</tr>
<tr>
<td>Temporomandibular disorders</td>
<td>311–326</td>
</tr>
<tr>
<td>arthralgia, 323t</td>
<td>318</td>
</tr>
<tr>
<td>treatment, 323t</td>
<td>325</td>
</tr>
<tr>
<td>behavioral/psychologic factors, 312</td>
<td>312</td>
</tr>
<tr>
<td>management, 325</td>
<td>325</td>
</tr>
<tr>
<td>bruxism</td>
<td>325</td>
</tr>
<tr>
<td>classification</td>
<td>314</td>
</tr>
<tr>
<td>clicking</td>
<td>312</td>
</tr>
<tr>
<td>clinical assessment</td>
<td>313–314</td>
</tr>
<tr>
<td>computed tomography</td>
<td>317, 319, 321</td>
</tr>
<tr>
<td>Coronoid impingement</td>
<td>318</td>
</tr>
<tr>
<td>degenerative remodeling</td>
<td>313</td>
</tr>
<tr>
<td>diagnostic blocks</td>
<td>318</td>
</tr>
<tr>
<td>disc displacement</td>
<td>313, 320</td>
</tr>
<tr>
<td>reduction, 323t</td>
<td>323t</td>
</tr>
<tr>
<td>treatment, 322, 323t</td>
<td>325</td>
</tr>
<tr>
<td>epidemiology</td>
<td>311–312</td>
</tr>
<tr>
<td>etiology</td>
<td>311–312</td>
</tr>
<tr>
<td>hematoma</td>
<td>319, 321</td>
</tr>
<tr>
<td>imaging techniques</td>
<td>315–318</td>
</tr>
<tr>
<td>infection</td>
<td>319</td>
</tr>
<tr>
<td>jaw parafunction</td>
<td>325</td>
</tr>
<tr>
<td>joint sounds</td>
<td>312</td>
</tr>
<tr>
<td>laboratory studies</td>
<td>318</td>
</tr>
<tr>
<td>limited opening</td>
<td>318–320</td>
</tr>
<tr>
<td>magnetic resonance imaging</td>
<td>317, 319, 320</td>
</tr>
<tr>
<td>management</td>
<td>320–325</td>
</tr>
<tr>
<td>metastatic disease</td>
<td>314</td>
</tr>
<tr>
<td>microtrauma</td>
<td>313</td>
</tr>
<tr>
<td>muscle dysfunction</td>
<td>313</td>
</tr>
<tr>
<td>occlusion changes</td>
<td>314–318</td>
</tr>
<tr>
<td>open bite</td>
<td>314, 316</td>
</tr>
<tr>
<td>pain, 303, 311, 323t</td>
<td>323</td>
</tr>
<tr>
<td>referred</td>
<td>323</td>
</tr>
<tr>
<td>tension type headache</td>
<td>312</td>
</tr>
<tr>
<td>treatment, 321</td>
<td>321</td>
</tr>
<tr>
<td>trigger point</td>
<td>323</td>
</tr>
<tr>
<td>panoramic radiography</td>
<td>317</td>
</tr>
<tr>
<td>pathophysiology</td>
<td>313</td>
</tr>
<tr>
<td>patient assessment</td>
<td>313, 314</td>
</tr>
<tr>
<td>prevalence</td>
<td>311–312</td>
</tr>
<tr>
<td>radioactive bone scan</td>
<td>317–318, 320</td>
</tr>
</tbody>
</table>
repositioning appliances, 321
Research Diagnostic Criteria, 314
- diagnosis, 316
  - examination components, 315t
self-therapy, 325
sleep dysfunction, 321
splint therapy, 321–322
structural changes, 314–318
tomograms, 317, 318
- treatment protocol checklist, 324
Temporomandibular joint, 17–19
Tetralogy of Fallot, 29
Thalassemia, 68–69
Thiazolidinediones, 89
Thigmotropism, 171
Thionamides, 98
during pregnancy, 98
Thrombocytopenia, 62, 64
dental implications, 65–66
Thrush, 136, 171
Thyroid gland, 17, 96
Thyroid hormone regulation, 96, 97
Thyrotoxicosis, 96, 98
- crisis, 98
dental management, 98
Thyroxine (T4), 96
Tongue, 14
  - bald, 59
  - burning, 90
  - candidiasis, 172
  - carcinoma, 199
  - changes to, 58, 70
denudation, 58
dysesthesia, 40
erythematous candidiasis, 135, 136
  - examining, 12–13, 23
fissured, 235, 256
geographic, 254–255
glossitis, 70
hairy leukoplakia, 138
hairy, 224, 225, 253–254
hemiangioma, 258
syphilis, 167
ulcerations, 120
Tooth color
  - green, 56, 156
Toxicity, 107t, 108, 109t
  - overdose, 108
Traumatic fibroma, 231–232
Traumatic ulcerative granuloma with stromal eosinophilia, 249–250
Trigeminal nerve, 21, 23, 279
  - assessing, 22
  - Trigeminal neuralgia, 340–342
  - Trigeminal system, 295–297
deaferentation, 296
pain transmission, 291–295
Triiodothyronine (T3), 96
Trocklear nerve, 21, 22
Tuberculosis, 44–45
  - and Addison disease, 94
  - clinical manifestations, 49
  - military, 45
  - oral manifestations, 51, 52
  - precautions, 181
  - secondary, 44
Tuberculous lymphadenitis, 51
Tuberosity, 11, 13
Tubulointerstitial disease, 37
Tumor suppressor genes, 190–191
  - classification, 194, 196t
Tyrosinase, 219
Ulcerative colitis, 58, 59
Ulcers, oral, 58–60
Uremia, 36, 38, 39
Uremic syndrome, 38
Urobilinogen, 55
Vaccination, health care workers, 181–182
Vagus nerve, 23, 278
Valvular insufficiency, 29–30
Valvular stenosis, 29–30
Varicella-zoster virus, 122–123
in HIV, 139
Varices, focal, 234–235, 237
Venipuncture, 23–24
Ventricular fibrillation, 31
Verruca vulgaris, 147, 151
Vertigo, 335
Viral infection, 137–140
in myelosuppressed patient, 77
Virions, 117
Vitamin B12, 58
deficiency, 69
Vitamin D, 100
Vitamin K, 64, 65
Vocal structures, 16, 18
von Willebrand factor, 61, 63–66
Warts, 140
Weber test, 20, 21
Wegener granulomatosis, 230, 237
  - clinical features, 234, 249
giant cells, 249
treatment, 251
Wharton duct, 262
White sponge nevus, 257
  - genetic/molecular investigations, 252–253
Xerostomia, 81–82, 260–269
  - causes, 261
  - complications, 135
dental caries, 268
differential diagnosis, 264–267
in diabetes, 91
in HIV, 135
radiation-induced, 202
treatment, 135, 268–269